Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review

Paola Rogliani,Gian Marco Manzetti,Federica Roberta Bettin,Maria D’Auria,Luigino Calzetta
DOI: https://doi.org/10.1080/13543784.2024.2305144
2024-01-18
Expert Opinion on Investigational Drugs
Abstract:Introduction Severe asthma patients often remain uncontrolled despite high-intensity therapies. Biological therapies targeting thymic stromal lymphopoietin (TSLP), a key player in asthma pathogenesis, have emerged as potential options. Currently, the only TSLP inhibitor approved for the treatment of severe asthma is the immunoglobulin G (IgG) 2λ anti-TSLP monoclonal antibody (mAb) tezepelumab.
pharmacology & pharmacy
What problem does this paper attempt to address?